Veille Pharma
20.7K views | +0 today
Veille Pharma
Chargé d'affaires chez Patientsworld. Mes posts n'engagent que moi.
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

Publication dans la version en ligne du Journal of Clinical Oncology d’une étude de phase I/II évaluant le potentiel clinique d’ABRAXANE® sur les patients atteints d'un cancer du pancréas à un stad...

Publication dans la version en ligne du Journal of Clinical Oncology d’une étude de phase I/II évaluant le potentiel clinique d’ABRAXANE® sur les patients atteints d'un cancer du pancréas à un stad... | Veille Pharma | Scoop.it

Celgene International Sarl a annoncé aujourd’hui que les résultats d’une étude clinique d’ABRAXANE (nanoparticules de paclitaxel liées à l'albumine pour suspension injectable) pris en association avec la gemcitabine, réalisée auprès de 67 patients atteints d’un cancer du pancréas à un stade avancé non précédemment traité, ont été publiés dans un article en ligne par le Journal of Clinical Oncology avant la sortie de la version imprimée.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Research Interest in Bevacizumab Remains Robust

Research Interest in Bevacizumab Remains Robust | Veille Pharma | Scoop.it

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

FDA warns of Avastin's risk of infertility in women

FDA warns of Avastin's risk of infertility in women | Veille Pharma | Scoop.it

US regulators have updated the label of Roche's Avastin (bevaicuzumab) to warn about the possible risk of infertility in some women taking the cancer drug. The FDA said that the product's label effective September 30 now includes a warning regarding “ovarian failure” and recommended that doctors inform women of child-bearing age of the risk.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Afinitor Delays Progression of Advanced Breast Cancer

Afinitor Delays Progression of Advanced Breast Cancer | Veille Pharma | Scoop.it

Among postmenopausal women with advanced breast cancer that had become resistant to hormonal therapy, the combination of Afinitor® (everolimus) and Aromasin® (exemestane) delayed cancer progression to a greater extent than Aromasin alone. The results of this Phase III clinical trial were presented at the 2011 European Multidisciplinary Cancer Congress.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Revue Stratégique 2011 : De nouveaux traitements pour le cancer de la prostate devraient faire passer ce marché au niveau mondial de 4 à 8,9 milliards de dollars à l’horizon 2019

Après la chirurgie ou la radiothérapie, les patients atteints d’un cancer de la prostate sont typiquement traités par Lupron, (leuprolide) ou d’autres inhibiteurs de la production de testostérone.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Roche's Avastin set for new ovarian cancer indication in Europe

Roche's Avastin set for new ovarian cancer indication in Europe | Veille Pharma | Scoop.it

Roche’s Avastin has gained the backing of European regulatory advisors for a new indication in ovarian cancer.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Adding Novartis's Afinitor to Pfizer Drug Extends Cancer Patients' Lives

Adding Novartis's Afinitor to Pfizer Drug Extends Cancer Patients' Lives | Veille Pharma | Scoop.it

Novartis AG (NOVN)’s kidney-cancer drug Afinitor also prevented breast cancer from worsening in a study that the Swiss drugmaker plans to use in applying for regulatory approval.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Novartis releases positive results from Bolero-2 Phase III trial

Novartis' Bolero-2 Phase III double-blind, randomized, multicenter, placebo-controlled study demonstrated that Afinitor (everolimus) tablets plus exemestane more than doubled the time women lived without tumor growth (progression-free survival; PFS).

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for a Fatal Form of Lung Cancer

ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for a Fatal Form of Lung Cancer | Veille Pharma | Scoop.it

INDIANAPOLIS, September 26, 2011 /PRNewswire/ -- Eli Lilly And Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of ALIMTA(R) (pemetrexed for injection) as continuation maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Positive opinions from the CHMP are reviewed by the European Commission, which then decides on whether to grant marketing authorization in Europe.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Millennium et Seattle Genetics présentent, à l’n deoccasio la réunion annuelle de l’EMCC, des données cliniques concernant l’utilisation d’ADCETRIS™ (Brentuximab Vedotin) chez les patients pédiatri...

Millennium et Seattle Genetics présentent, à l’n deoccasio la réunion annuelle de l’EMCC, des données cliniques concernant l’utilisation d’ADCETRIS™ (Brentuximab Vedotin) chez les patients pédiatri... | Veille Pharma | Scoop.it

CAMBRIDGE, Massachusetts et BOTHELL, Washington--(BUSINESS WIRE)--Millennium : la Société d'oncologie Takeda, une filiale en propriété exclusive de Takeda Pharmaceutical Company Limited (TSE : 4502) et Seattle Genetics, Inc. (Nasdaq : SGEN), ont publié aujourd’hui les résultats d’une analyse rétrospective de patients pédiatriques (12 – 17 ans) recrutés dans le cadre de quatre essais cliniques multicentriques (deux essais de phase I et deux essais de phase II) d’ADCETRIS. Tous les patients étaient diagnostiqués avec un lymphome hodgkinien récurrent ou réfractaire (n=5) ou un lymphome anaplasique à grandes cellules systémique (n=4) et sur lesquels au moins un protocole de chimiothérapie a échoué dans le passé. Les résultats ont été publiés aujourd’hui lors d’une présentation orale à l’occasion de la réunion annuelle de l’EMCC (European Multidisciplinary Cancer Congress) qui se tient à Stockholm, en Suède, du 23 au 27 septembre.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ESMO Clinical Practice Guidelines - European Society for Medical Oncology (ESMO)

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. Each CPG includes information on the incidence of the malignancy, diagnostic criteria, staging of disease and risk assessment, treatment plans and follow-up.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2–Normal, Node-Positive Br...

Purpose Anthracyclines, taxanes, and alkylating agents are among the most active agents in treatment of adjuvant breast cancer (BC), but the optimal schedule for their administration is unknown. We performed an adjuvant trial to compare the sequential regimen of doxorubicin with cyclophosphamide (AC) followed by docetaxel (ie, AC>T) with the combination regimen of TAC.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Long-Term Painkiller Use Linked to Kidney Cancer

Long-Term Painkiller Use Linked to Kidney Cancer | Veille Pharma | Scoop.it

Long-term, regular use of non-aspirin anti-inflammatory painkillers raises the likelihood of developing kidney cancer by more than 50%, a study shows.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership

Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership | Veille Pharma | Scoop.it

SAN FRANCISCO, Oct. 12, 2011 /PRNewswire/ -- Today Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX - News) and Bayer HealthCare restructured their partnership for the global development and marketing of Nexavar® (sorafenib) tablets and entered into a new agreement related to regorafenib, a late-stage oncology compound.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor

WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Merck (NYSE:MRK - News), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA - News), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy. The FDA assigned a Standard review classification to this application.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

As maintenance therapy in locally advanced or metastatic NSCLC, pemetrexed is no longer restricted to only follow specific combinations of platinum-based chemotherapy

On 22 September 2011, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product pemetrexed (Alimta). The marketing authorization holder for this medicinal product is Eli Lilly Nederland B.V. They may request a re examination of the CHMP opinion, provided that they notify the European Medicines Agency in writing of their intention within 15 days of receipt of the opinion.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

European Medicines Agency extends therapeutic indications for bevacizumab

Bevacizumab in combination with carboplatin and paclitaxel is now indicated for the front-line treatment of advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Article > Targeted anticancers should mean smaller trials, researchers argue

Article > Targeted anticancers should mean smaller trials, researchers argue | Veille Pharma | Scoop.it

Targeted anticancers should mean smaller trials, researchers argue


more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Rupture de stock imminente en Caelyx - Point d’information - AFSSAPS : Agence française de sécurité sanitaire des produits de santé

L’Afssaps informe de la rupture de stock imminente d’un médicament utilisé dans les chimiothérapies anticancéreuses, le Caelyx, qui va déboucher sur une impossibilité d’approvisionnement totale et probablement prolongée.En conséquence, il est demandé aux prescripteurs de ne pas initier de nouveaux traitements par Caelyx et de prescrire un autre médicament autorisé pour le traitement des patients actuellement traités ou qui auraient pu en bénéficier.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Cancer de la vessie: Ipsen acquiert de Photocure les droits d’Hexvix®

Cancer de la vessie: Ipsen acquiert de Photocure les droits d’Hexvix® | Veille Pharma | Scoop.it

Ipsen a annoncé aujourd’hui un partenariat avec Photocure, une entreprise pharmaceutique norvégienne spécialisée dans les technologies photodynamiques appliquées au cancer et à la dermatologie. Dans le cadre de cette collaboration stratégique, Ipsen commercialisera dans le monde entier – à l’exception des Etats-Unis et de la Scandinavie – Hexvix®, le produit phare de Photocure pour le diagnostic et la résection du cancer de la vessie.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

ECCO-ESMO: Antibody-Chemo Combo Promising in Breast Cancer

ECCO-ESMO: Antibody-Chemo Combo Promising in Breast Cancer | Veille Pharma | Scoop.it

STOCKHOLM -- A novel monoclonal antibody-guided therapy for HER2-positive metastatic breast cancer extended disease-free survival compared with standard treatment, researchers said here.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Cancer du sein métastatique: résultats positifs pour le T-DM1, un médicament expérimental de Roche

Cancer du sein métastatique: résultats positifs pour le T-DM1, un médicament expérimental de Roche | Veille Pharma | Scoop.it

Le groupe pharmaceutique suisse Roche a communiqué ce week-end les résultats de l’étude de phase II TDM4450g menée chez des patientes souffrant de cancer du sein métastatique (CSm) HER2-positif non précédemment traité. L’étude a comparé le trastuzumab emtansine (connu sous l’appellation T-DM1) au traitement standard par Herceptin (trastuzumab) plus chimiothérapie par le docétaxel.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors | Veille Pharma | Scoop.it

Purpose : Preclinical studies demonstrate synergistic anti-tumor activity with the combination of everolimus and cisplatin. We conducted a phase I study to establish the recommended phase II of oral everolimus to be given with low-dose weekly intravenous cisplatin.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Avant 40 ans, la tumorectomie est une option sure pour le cancer du sein  | Medscape France

Selon deux études présentées au Breast Cancer Symposium 2011, le traitement conservateur présente des taux de récidive locale et de survie équivalents à la mastectomie chez les femmes jeunes atteintes d'un cancer du sein.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Novartis claims Amgen's Xgeva not cost-effective in breast cancer-related bone metastases - APM Health Europe

Lien sous abonnement

more...
No comment yet.